Media

Conference

Safety & Recalls
Regulatory Updates
Drug Coverage
COPD
Cardiovascular
Obstetrics-Gynecology & Women's Health
Ophthalmology
Clinical Pharmacology
Pediatrics
Urology
Pharmacy
Idiopathic Pulmonary Fibrosis
Diabetes and Endocrinology
Allergy, Immunology, and ENT
Musculoskeletal/Rheumatology
Respiratory
Psychiatry and Behavioral Health
Dermatology
Oncology

Atomoxetine displays long-term efficacy in adult patients with ADHD

July 1, 2003

Article

Long-term treatment of 384 adults ADHD patients with atomoxetine (Strattera, Lilly) showed that 67% responded with at least a 30% improvement and 40% had at least a 50% improvement.

Related Content

FDA Committee Recommends Sanofi/AstraZeneca’s RSV Vaccine for Infants

June 12th 2023

Article

If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.

FDA Approves First Pediatric Indication for Blockbuster Eylea

February 9th 2023

Article

Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.

FDA Accepts BLA for RSV Prevention in Infants

January 5th 2023

Article

Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.

Wegovy Approved for Teens; Supply May be Delayed

January 4th 2023

Article

Wegovy is a once-weekly prescription medication for obesity that has faced supply issues. Its manufacturer, Novo Nordisk, is increasing production capacity in 2023.

AbbVie Submits sNDA for Linzess for Children and Adolescents

December 17th 2022

Article

If approved, Linzess would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age.

FDA Grants Six Months Pediatric Exclusivity for Eylea

October 21st 2022

Article

Eylea is being reviewed as a treatment for retinopathy in premature infants.

Related Content

FDA Committee Recommends Sanofi/AstraZeneca’s RSV Vaccine for Infants

June 12th 2023

Article

If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.

FDA Approves First Pediatric Indication for Blockbuster Eylea

February 9th 2023

Article

Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.

FDA Accepts BLA for RSV Prevention in Infants

January 5th 2023

Article

Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.

Wegovy Approved for Teens; Supply May be Delayed

January 4th 2023

Article

Wegovy is a once-weekly prescription medication for obesity that has faced supply issues. Its manufacturer, Novo Nordisk, is increasing production capacity in 2023.

AbbVie Submits sNDA for Linzess for Children and Adolescents

December 17th 2022

Article

If approved, Linzess would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age.

FDA Grants Six Months Pediatric Exclusivity for Eylea

October 21st 2022

Article

Eylea is being reviewed as a treatment for retinopathy in premature infants.

Advertise

Editorial Info

Terms & Conditions

Do Not Sell My Personal Information